ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,194 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryReinach BlSunRegen Healthcare AG
SunRegen Healthcare AG Logo
Verified· 3 sources

SunRegen Healthcare AG

Summary

About the company

The core activity of SunRegen Healthcare AG is the development of medications for the treatment of neurodegenerative diseases, particularly retinal neurodegenerations such as Retinitis Pigmentosa, age-related macular degeneration and glaucoma, as well as central nervous system neurodegenerations such as Alzheimer's, Huntington's, Parkinson's and ALS. The company focuses on the development of oral therapeutics that inhibit neuronal apoptosis and exhibit neuroprotective effects.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered4
Oral Neurodegeneration Therapy (SBC003)
Oral small-molecule therapy for retinal and CNS neurodegeneration, with neuroprotective, neuro-rescuing and neurotrophic effects; in development for retinitis pigmentosa, dry AMD and optic atrophy.
Drug Development Pipeline for Retinal and CNS Diseases
Development pipeline covering IND-enabling work, preclinical development and indication expansion for retinitis pigmentosa, dry AMD, optic atrophy and CNS neurodegeneration.
Scientific Collaborations and Platform Licensing
Research and clinical-development partnerships, including platform licensing for compounds across retinal and CNS indications plus CRO, CMO and academic collaborations.
Equity Financing for Clinical Development
Series A financing to fund IND submission and Phase I/II trials in retinitis pigmentosa, aimed at institutional life science investors and strategic partners.
Press

Media

August 20, 2024Media
SunRegen Healthcare to go public via reverse takeover
startupticker.ch
Comparisons

SunRegen Healthcare AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank SunRegen Healthcare AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of SunRegen Healthcare AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Robinienweg 51
4153 Reinach Bl

At a glance

Legal form
Corporation
UID
CHE-295.245.274
Founded
2017 · 9 years
Last commercial register change
July 7, 2025
Employees
1 to 10

Knowledge

No knowledge articles yet

Once SunRegen Healthcare AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

BA
Baliopharm AG
Reinach Bl
TP
T3 Pharmaceuticals AG
Allschwil
SP
Santhera Pharmaceuticals (Schweiz) AG
Pratteln
ST
saverna therapeutics AG
Biel-Benken Bl
IA
InCephalo AG
Allschwil
CT
CAPTOR THERAPEUTICS GmbH
Allschwil
EA
EpiPharm AG
Binningen
PP
Perseo pharma AG
Muttenz